HOME >> MEDICINE >> NEWS
Stents that release medication appear more effective than traditional stents

A type of coronary artery stent that releases a medication appears to result in better outcomes than traditional stents for heart attack patients, according to a study in the May 4 issue of JAMA.

Sirolimus, a substance that is thought to help prevent reclosure of coronary arteries, can be released from certain types of stents (metal devices inserted to keep a coronary artery open after angioplasty) to greatly reduce the need for target-vessel revascularization (TVR) compared with bare-metal stents (i.e., stents without medication), according to background information in the article. These drug-eluting stents have the potential to further improve long-term clinical outcome after primary percutaneous coronary intervention (PCI), such as angioplasty. However, the lack of randomized trials to assess the safety and long-term efficacy of sirolimus-eluting stent implantation in patients with acute ST-segment elevation (a certain measurement on an electrocardiogram) myocardial infarction (STEMI), in conjunction with the expected financial consequences, currently limit use of sirolimus-eluting stents in this setting. Current clinical guidelines specifically recommend the drug abciximab during primary PCI. At current European list prices, the use of the drug tirofiban instead of abciximab would absorb the difference in cost between stenting with sirolimus-eluting vs. bare-metal stents.

Marco Valgimigli, M.D., of the University of Ferrara, Italy and colleagues compared angiographic and clinical outcomes for the treatments of high-dose tirofiban plus sirolimus-eluting stenting vs. a current preferred strategy for STEMI treatment, pretreatment with abciximab plus bare-metal stenting. The STRATEGY trial included 175 patients presenting to a single referral center in Italy with STEMI or presumed new left bundle-branch block between March 6, 2003 and April 23, 2004. Patients received either tirofiban regimen plus sirolimus-eluting stenting (n = 87) or abciximab pl
'"/>

Contact: Marco Valgimigli
vlgmrc@unife.it
JAMA and Archives Journals
3-May-2005


Page: 1 2 3

Related medicine news :

1. ACC/AHA release revised UA/NSTEMI guidelines
2. NIAID releases MDR/XDR Tuberculosis research agenda
3. FDA approves ZYFLO CR extended-release tablets for chronic treatment of asthma
4. JRRD releases single-topic issue on pain and pain management
5. New prostate cancer clinical guidelines to be released
6. Physicians should be able to review performance rates before release
7. New reflux guidelines released
8. Groundbreaking principles on sexual orientation and human rights released
9. American College of Physicians releases new patient education resources
10. Joint Principles of PC-MH released by organizations representing more than 300,000 physicians
11. Slow-release morphine reduces level of intractable cough

Post Your Comments:
(Date:3/4/2015)... 04, 2015 In a small ceremony with ... on their new facility in New Port Richey on February ... new facility will allow the Florida drug detox facility ... drug abuse epidemic through treatment and education. “Due to our ... in the United States, we made the decision that expanding ...
(Date:3/4/2015)... (PRWEB) March 04, 2015 Jeannie Mai, TV ... “The Real” graces the cover of the print publication. Mai ... to choose organic when shopping for clothes and personal care ... opens up about her commitment to an organic diet. She ... energy, not only in gymnastics, but also now as I’m ...
(Date:3/4/2015)... Hoersholm, DK (PRWEB) March 04, 2015 ... of Dako , has joined the Visiopharm ... joins Visiopharm at a time when we are positioned ... quantitative digital pathology for cancer diagnostics and research. ... invested significantly in the development and validation of ONCOtopix™ ...
(Date:3/4/2015)... (PRWEB) March 04, 2015 Problem Gambling ... time to join individuals and organizations across the nation ... general public, health care professionals, policymakers, and others about ... Council on Compulsive Gambling (FCCG) and FCCG partner organizations ... to screen patients for a gambling problem, to make ...
(Date:3/4/2015)... A new dieting routine, called the ... of extending life. Studies conducted by the ... routine can help extend life by increasing anti-oxidant production. ... term benefits, many suffering from obesity are already experiencing ... necessary. As an alternative to the new Feast and ...
Breaking Medicine News(10 mins):Health News:Novus Medical Detox Hosts Ribbon Cutting Ceremony at Pasco County Facility 2Health News:Novus Medical Detox Hosts Ribbon Cutting Ceremony at Pasco County Facility 3Health News:Visiopharm Appoints Patrik Dahlen as Chairman of the Board 2Health News:Visiopharm Appoints Patrik Dahlen as Chairman of the Board 3Health News:Problem Gambling - A Public Health Issue; March Is Problem Gambling Awareness Month 2Health News:Diet Doc Introduces New Alternative to the Feast and Famine Diet 2Health News:Diet Doc Introduces New Alternative to the Feast and Famine Diet 3
(Date:3/3/2015)... DUBLIN , March 3, 2015 Actavis ... it has priced an offering of $21 billion aggregate ... in a registered public offering to be issued by ... by certain of its other subsidiaries (the "Notes"), as ... to PublicFloating Rate Senior Notes* , $500,000,000 ...
(Date:3/3/2015)... Medical Tracking Solutions, Inc., developers of ... Brian Timberlake as Senior Vice President ... build relationships with existing and new clients. Brian brings ... and sales management as well as a deep ... comprehensive inventory management system that provides real-time tracking ...
(Date:3/3/2015)... March 3, 2015 Boston Scientific Corporation (NYSE: ... Dockendorff and Stephen P. MacMillan to its ... of the board, Uwe E. Reinhardt and ... the company,s annual meeting of stockholders in May 2015. ... executive vice president and chief financial officer of Covidien plc. ...
Breaking Medicine Technology:Actavis Announces Pricing of Public Offering of Senior Notes in Connection with Pending Acquisition of Allergan 2Actavis Announces Pricing of Public Offering of Senior Notes in Connection with Pending Acquisition of Allergan 3Actavis Announces Pricing of Public Offering of Senior Notes in Connection with Pending Acquisition of Allergan 4Actavis Announces Pricing of Public Offering of Senior Notes in Connection with Pending Acquisition of Allergan 5Actavis Announces Pricing of Public Offering of Senior Notes in Connection with Pending Acquisition of Allergan 6Actavis Announces Pricing of Public Offering of Senior Notes in Connection with Pending Acquisition of Allergan 7Actavis Announces Pricing of Public Offering of Senior Notes in Connection with Pending Acquisition of Allergan 8Actavis Announces Pricing of Public Offering of Senior Notes in Connection with Pending Acquisition of Allergan 9Actavis Announces Pricing of Public Offering of Senior Notes in Connection with Pending Acquisition of Allergan 10Medical Tracking Solutions, Inc. Hires New SVP, Sales 2Boston Scientific Elects Charles J. Dockendorff And Stephen P. MacMillan To Board Of Directors 2
Cached News: